Medpace (NASDAQ:MEDP) Stock Price Expected to Rise, Truist Financial Analyst Says

Medpace (NASDAQ:MEDP) had its price objective increased by Truist Financial from $462.00 to $609.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price points to a potential upside of 0.29% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and lifted their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday. Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, TD Cowen increased their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $560.92.

Medpace Stock Performance

Medpace stock traded up $1.39 during trading on Friday, hitting $607.21. The company’s stock had a trading volume of 213,207 shares, compared to its average volume of 357,295. The stock has a market capitalization of $17.34 billion, a price-to-earnings ratio of 35.56, a P/E/G ratio of 2.64 and a beta of 1.15. The stock’s fifty day moving average is $488.37 and its 200 day moving average is $493.74. Medpace has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 109.14%. Medpace’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace will post 17.04 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BOKF NA grew its stake in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in shares of Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares in the last quarter. UMB Bank n.a. boosted its holdings in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares during the last quarter. Schulhoff & Co. Inc. grew its stake in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC grew its stake in Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported Q2 EPS of $4.25, beating estimates, while revenue of $707.3 million also topped expectations and rose 17.2% year over year. Article Title
• Positive Sentiment: The company raised FY 2026 guidance to EPS of 17.25-17.95 and revenue of about $2.8 billion-$2.9 billion, signaling stronger full-year growth expectations. Article Title
• Positive Sentiment: Analysts and market reports highlighted a big bookings beat, a rebound in the book-to-bill ratio, and stronger backlog conversion, which improve revenue visibility and support the growth story. Article Title
• Positive Sentiment: Medpace reached a 52-week high, reflecting renewed confidence in the stock after the earnings beat and improved outlook. Article Title
• Neutral Sentiment: Robert W. Baird raised its price target on Medpace to $624 from $547 but kept a neutral rating, suggesting the valuation already reflects much of the recent upside. Article Title

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.